Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 3/20 | 0.34 |
| ▸ | TOP2A | P11388 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | PDE5A | O76074 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5895662 | 1.00 | HTR2A (0.41) | HTR2AHTR2CHTR2BRIPK1KMT2A | |
| SCHEMBL5764755 | 0.85 | TOP2A (0.42) | HTR2AHTR2CHTR2BRIPK1TOP2A | |
| SCHEMBL5764751 | 0.85 | TOP2A (0.42) | HTR2AHTR2CHTR2BRIPK1TOP2A | |
| SCHEMBL5765162 | 0.85 | TOP2A (0.42) | HTR2AHTR2CHTR2BRIPK1TOP2A | |
| SCHEMBL8040229 | 0.81 | HTR2C (0.36) | HTR2AHTR2CHTR2BKMT2AHTR7 | |
| SCHEMBL6104505 | 0.80 | HTR2C (0.42) | HTR2AHTR2CHTR2BRIPK1MAOA | |
| SCHEMBL7499691 | 0.80 | HTR2C (0.42) | HTR2AHTR2CHTR2BRIPK1MAOA | |
| SCHEMBL6105509 | 0.77 | PDE4B (0.47) | RIPK1GRM5 | |
| SCHEMBL6105507 | 0.77 | PDE4B (0.47) | RIPK1GRM5 | |
| SCHEMBL7006697 | 0.77 | PDE4B (0.47) | RIPK1GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7091211-B2 | Cyclopentyl modulators of chemokine receptor activity | MERCK & CO., INC. (US) | 2006-08-15 | — | — | US | disclosed |
| US-20050070609-A1 | Cyclopentyl modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2005-03-31 | — | — | US | disclosed |
| US-6432981-B1 | BLOCKS HUMAN IMMUNODEFICIENCY VIRUS (HIV) FROM ENTERING CELLS; AUTOIMMUNE DISEASES; ANTIALLERGENS, ANTIINFLAMMATORY AND ANTIASTHMATIC AGENTS | MERCK & CO., INC. | 2002-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070609-A1 | Cyclopentyl modulators of chemokine receptor activity | CCR5, CXCR1, ACKR3 | HTR2A 2000/4885HTR2C 2397/4885HTR2B 1814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.